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Abstract
Background: Personalized medicine has the potential to allow patients to receive drugs specific to their individual
disease, and to increase the efficiency of the healthcare system. There is currently no comprehensive overview of
personalized medicine, and this research aims to provide an overview of the concept and definition of personalized
medicine in nine European countries.
Methods: A targeted literature review of selected health databases and grey literature was conducted to collate
information regarding the definition, process, use, funding, impact and challenges associated with personalized
medicine. In-depth qualitative interviews were carried out with experts with health technology assessment, clinical
provisioning, payer, academic, economic and industry experience, and with patient organizations.
Results: We identified a wide range of definitions of personalized medicine, with most studies referring to the use of
diagnostics and individual biological information such as genetics and biomarkers. Few studies mentioned patients’
needs, beliefs, behaviour, values, wishes, utilities, environment and circumstances, and there was little evidence in the
literature for formal incorporation of patient preferences into the evaluation of new medicines. Most interviewees
described approaches to stratification and segmentation of patients based on genetic markers or diagnostics, and few
mentioned health-related quality of life.
Conclusions: The published literature on personalized medicine is predominantly focused on patient stratification
according to individual biological information. Although these approaches are important, incorporation of environmental
factors and patients’ preferences in decision making is also needed. In future, personalized medicine should move from
treating diseases to managing patients, taking into account all individual factors.
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Background
With many new drugs designed against specific targets
the use of biomarkers will increasingly allow patients to
receive the drug most likely to be effective for their dis-
ease. In parallel, there is an increasing awareness that the
different administration regimens and side effect profiles
associated with particular therapies can impact health-
related quality of life (HRQoL) in ways that vary among
individuals. Differences also exist among patients with re-
gard to benefit–harm trade-offs and willingness to obtain
the best possible care, and individuals may benefit from
holistic solutions adapted to their individual profile and
preferences. These approaches could be applied to the
majority of procedures and pharmacological agents, not
just targeted therapies. Using biomarkers to target therap-
ies is regarded by some as a way towards a more efficient
and cost-effective healthcare system [1–4]. This is particu-
larly important as across Europe ageing populations and
the increasing prevalence of chronic disorders are placing
healthcare budgets under pressure. As a result, healthcare
systems are increasingly mindful of budget impact and
cost-effective usage of expensive innovative agents.
Personalized medicine (PM) is a relatively young field, al-
though there have been a substantial number of recent
publications in the area of PM and how it could be facili-
tated and implemented [3, 5, 6]. Different stakeholders’
views on PM may reflect different aspects of the overall
concept, and a comprehensive overview of what is
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understood by the term PM (also referred to as ‘stratified
medicine’), and exactly what benefits and challenges may
be associated with its implementation, is needed.
Therefore, the purpose of this research was to provide
an overview of the concept of PM in Europe, with a par-
ticular focus on how patient segmentation is currently
performed in nine countries with different healthcare
systems: Austria, France, Germany, Hungary, Italy, the
Netherlands, Spain, Sweden and the UK. In addition, we
sought to identify some of the challenges and opportun-
ities of PM in terms of providing the greatest possible
value both for individual patients and society.
To meet these goals, we first conducted a targeted lit-
erature review of selected health databases and grey litera-
ture with the aim of collating qualitative information
regarding the definition, process, use, funding, impact on
health technology assessment (HTA) evaluation and chal-
lenges associated with PM. We decided to perform a
qualitative literature review limiting the search to the se-
lected European countries, and the findings were taken
into account during the elaboration and validation of in-
terviews. Second, because PM is an evolving field, and to
capture an up-to-date picture of how PM is viewed across
Europe, we carried out in-depth qualitative interviews
with a range of experts with HTA, clinical provisioning,
payer, academic, economic and industry experience, while
members of patient associations were also interviewed. Fi-
nally, we describe some of the challenges that will need to
be overcome in order to integrate patients’ preferences
into PM decision-making processes.
Methods
Literature review
Searches of the MEDLINE and Embase databases were
carried out between October 2014 and February 2015
using terms specific to PM, including ‘personalized
medicine’, ‘individualized medicine’, ‘stratified medicine’,
‘segmented medicine’ and ‘targeted therapies’ according
to the PRISMA guidelines (see Additional file 1 for full
search terms). Electronic database searches were re-
stricted to English language only; dates searched were
2010 to present but limiting the survey to the nine se-
lected European countries. Similarly, grey literature
searches were performed for the nine countries of
interest – these searches were not limited to the Eng-
lish language and relevant materials were translated
where possible.
Literature was selected for inclusion in the review if it
addressed topics such as the definition of PM; methods
for patient segmentation; current HTA, reimbursement,
pricing and funding processes for PM; and the impact of
these on patient access (see Additional file 1 for
complete list).
The literature search in MEDLINE generated 1009 po-
tentially relevant titles and/or abstracts and was con-
ducted in October 2014. The Embase search generated
8580 potentially relevant titles and/or abstracts and was
conducted in February 2015. Due to the large number of
results in the Embase search the number of publications
from this specific search was reduced by first filtering
the initial results based on duplicates and additional
search terms (see Additional file 1).
Both the results from the MEDLINE search and the
remaining titles and/or abstracts from the Embase
search were filtered based on their relevance to the re-
search questions. For all relevant titles and abstracts, full
papers were reviewed, and relevant data were extracted
for evaluation. In case of doubt regarding the relevance
of a title abstract or paper, a second researcher was
consulted.
Based on those papers from the MEDLINE search that
were most interesting or provided information and/or
data that were scarce within the literature results, a cit-
ation search was conducted. In addition to the literature
searches carried out in MEDLINE and Embase, the ini-
tial search terms were also used to search for literature
on relevant websites. The identified literature was
screened, reviewed and filtered by a second researcher,
who also extracted data from the literature deemed
relevant.
Finally, the retrieved literature was analysed to identify
possible general themes related to PM, such as those
concerning the use of (bio)markers or patients’ prefer-
ences, which could refer to “traditional” or innovative at-
titudes in PM, respectively.
Expert interviews
Semi-structured, anonymized interviews were conducted
with experts from nine European countries, as well as
three experts from European patient organizations, and
one representative of the European Federation of
Pharmaceutical industries and Associations (EFPIA). Ex-
perts were recruited from a BresMed internal contact
list, and additional participants were recruited via snow-
ball sampling. Interview recruitment was double blinded:
the experts were not aware of the identity of the sponsor
or of the Authors, and vice versa, and this procedure
was explained to the experts during the administration
of the informed consent. Of note, the privacy of experts
was protected by excluding any information that could
identify the interviewees while the complete anonymiza-
tion of collected data was adopted before every analyses
were carried out and findings discussed.
An interview guide (see Additional file 2) was devel-
oped with open and closed questions based on themes
identified from the published evidence base and any ob-
vious gap in the collected and reviewed literature. Pilot
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interviews were conducted in February 2015 to address
any unclear or duplicated questions, and interviews with
experts were conducted between April and June 2015.
Interviewees were briefed about the objectives of the re-
search and gave their informed verbal consent to partici-
pate and for the interviews to be recorded. Interviewees
were asked about aspects of PM including definitions,
patient segmentation, assessment and implementation of
PM, the challenges they perceived personalized medicine
to be facing, potential solutions, and expectations of the
future of PM. The interviewer asked general questions
without forcing the expert toward a pre-classified
response.
Qualitative analysis was carried out through coding
the transcripts using a software program (NVivo 10,
QSR International) to identify any trends, differences
and similarities specific to the HTA and reimbursement
processes, decision making, challenges, and promoting
market access across the study countries. For presenta-
tion of the results, anonymity of participants was pro-
tected by removing names and creating broad interview
categories (e.g., clinical expert or economic expert).
Results
Literature review
The literature review revealed that there is no overall
consensus on how to define PM, with a number of dif-
ferent definitions in use [1–3, 5, 7–41] – in the literature
these ranged from “targeted treatment tailored to the
genetic makeup of individual tumours” [27] to “the idea
that medicines and other health technologies including
the prediction of individual risk may be customised to
each person’s specific genetic, physiological or psycho-
logical characteristics“[41]. In particular, the retrieved lit-
erature referred to two different semantic approaches
for PM: patients’ stratification (18 out of 38 articles), that
is grouping individual patients in subpopulation accord-
ing to their probability to have a therapeutic benefit
from a drug or regimen, and treatment tailoring (19 out
of 38), that is, the individual status of a patient (i.e., dis-
ease characteristics or subject’s genotype/phenotype) is
the rationale basis for drug choice. Interestingly, two pa-
pers did identify PM as a procedure that necessitates the
development of targeted agents [10, 18].
Most studies (30 out of 38) described the use of diag-
nostics and individual biological information, including
clinical characteristics, genetic disposition and biomarkers,
in order to target therapies to the patient and disease, with
the aim of improving outcomes and reducing side effects
(definitions are presented in Additional file 3 as exact quo-
tations from the original articles).
Reviewing the definitions, it clearly appears that
both stratification and tailoring may be based on
tests. Indeed, much of the published literature on
physiology-based PM concerns the use of genetic in-
formation and biomarkers to select patients for whom
a particular treatment is appropriate. Effective use of
biomarkers requires the availability of validated diag-
nostic tests, and a number of drug treatments have
specific companion diagnostics (CDs) [28, 42–44]. En-
suring that CDs are accessible is a major challenge in
the use of physiology-based PM, and the lack of sim-
ultaneous availability of both a drug and its CD is a
frequent issue in clinical practice. Processes for asses-
sing the clinical value and cost-effectiveness of CDs
are not well established, and a major limitation is that
assessments of drugs and CDs are often conducted
separately, and fail to capture the full benefits of
these products [28, 45]. The use of CDs may also be
associated with ethical issues (Table 1) [46].
It is worth noting that other stratification criteria used
are mostly demographic, and include factors such as age
and sex. A recent study by Schleidgen et al. (2013) [3]
has suggested a definition of PM as follows: “personal-
ized medicine seeks to improve stratification and timing
of health care by utilizing biological information and bio-
markers on the level of molecular disease pathways, gen-
etics, proteomics as well as metabolomics.”
By contrast, Rogowski et al. (2015) [38] reported the
results of a series of structured workshops, organized by
the International ONCOTYROL Expert Task Force [47],





• The process of getting consent from the patient for
testing is both lengthy and complex
Data
management
• Testing generates data which should be identifiable
and integrated into datasets of genomic and health
information
• Interpreting test data requires skilled professionals




• Translating the results to patients is becoming
increasingly difficult, as the number of biomarkers
being tested by a single test is constantly increasing
• Testing can provide incidental findings and variants
of unknown significance, knowledge of which can
affect a patient’s well-being
• Patients have concerns about privacy and the
possible disclosure of genetic information. They have
concerns about who sees their results during the
analysis process and a potential risk of discrimination if
such information is known
Cost and equity
issues
• The costs for targeted therapies are usually high;
drugs and accompanying tests might not always be
covered by health insurance, which can limit patients’
access to treatment
• High costs increase the imbalance in access to new
and better treatments as the identification of new
biomarkers and treatments continues
Guidelines • There is a lack of guidelines regarding implementation
of testing
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which supported the division of PM into physiology-
and preference-based PM [38]. The first category, also
termed ‘stratified medicine,’ refers to segmentation of pa-
tients according to their genetic makeup, while the sec-
ond refers to the tailoring of treatment according to
patients’ preferences.
In contrast to physiology-based approaches, a few papers
mentioned terms such as patients’ individual needs, beliefs,
behaviour, values, wishes, utilities, environment and circum-
stances in their definitions of PM [5, 8, 15, 16, 26, 38, 41].
Damato et al. (2013) [16] defined PM as “the tailoring of
therapy to the needs, wishes, fears, and condition of the pa-
tient, also taking account of the individual’s circumstances.”
The description by Rogowski et al. of preference-based PM
as developed by the ONCOTYROL Expert Task Force in-
cluded both revealed preferences such as adherence to treat-
ment and stated preferences such as attitude to risk [38].
In addition, a study by the European Commission rec-
ommended that the use of patient preferences in PM
should be increased [19]. Making treatment decisions in
conjunction with patients’ views does occur to a greater or
lesser extent in particular settings; however, there was lit-
tle evidence in the literature for formal incorporation of
patient preferences into the evaluation of new medicines.
Finally, the survey showed that PM has mainly a predict-
ive role (29/38 articles), being useful to anticipate the effi-
cacy of treatments, whereas only two of them [18, 31]
included the possibility to prevent “side effects” within the
definition. At the same time, only 13 papers stated that
PM has also a preventive role because it may determine
the individual “susceptibility to a particular disease”. In
turn, that knowledge allows the adoption of “preventive in-
terventions” aimed at reducing the risk.
Expert interviews
In total, 34 interviews were conducted with three patient
association members, one member of EFPIA, seven
academics, five clinicians, nine economists, five payers and
four providers (Table 2). The qualitative analysis of
interviews did not result in the identification of clear trends
across countries, and this was likely dependent on the lim-
ited number of experts. However, none of the interviewees
gave a specific definition of PM, even if most responses de-
scribed approaches to stratification and segmentation of
patients based on genetic markers or CDs in agreement
with the findings of literature survey. All respondents men-
tioned the use of tests or CDs to identify sub-groups, to
stratify patients to the right treatments, or to identify pa-
tients who might benefit the most from treatments. The
majority of experts (13 of 17 [76%]) believed that CDs were
important, but respondents generally felt valuing these
tools to be challenging, as their value is intrinsically linked
with the corresponding pharmaceutical product.
When asked about motivations for the segmentation
of patients (Table 3), the majority of experts used terms
associated with improvement of outcomes (14 of 20
[70%]) or optimization of side effect profiles (11 [55%]).
Another common reason for segmenting patients was to
avoid overtreatment or wasting resources (10 [50%]). In
addition, one of the patient representatives mentioned
that PM can also empower patients and clinicians: “… by
giving them knowledge about their condition, about their
genes, about the options they have and making them
more powerful when they are making informed choices.”
Another patient representative expressed concern that
patient segmentation should be conducted carefully: “…
I think there is a risk that precision medicine will be seen
to be an excuse for rationing, rather than a clinical tool
for better patient care.” Only two experts mentioned
HRQoL.
In total, eight respondents (of 34 [24%]; two clinicians,
two economists, two payers, one provider, and one aca-
demic) mentioned the incorporation of factors such as
environment and social setting in the treatment process,
but only one (payer [3%]) specifically mentioned pa-
tient’s preferences. By contrast, two experts (6%) stated
that they did not believe patient preferences to be im-
portant for patient segmentation.
Table 2 Distribution of external experts
Country Academic Clinical Economic Payer Provider Patient rep. EFPIA
Austria 1 1 1 3 1
France 1 1 1 1 1





The Netherlands 1 1 1 1 1
UK 1 1 1 1 1
EFPIA, the European Federation of Pharmaceutical Industries and Associations; rep., representative
Patient representatives were from European groups
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With regard to challenges in PM, several respondents
highlighted ethical concerns about patient segmentation.
For example, one clinician felt that using factors such as
age to stratify patients could be considered discrimin-
atory. Others noted that physicians can not force pa-
tients to undertake tests; if they refuse to take tests, they
cannot necessarily be refused treatment. There was a
clear feeling that more needs to be done to find reliable
ways to segment patients (7 of 15 [47%]), both to iden-
tify higher-risk patients and to prevent potentially in-
appropriate restrictions on access.
One limitation of PM that was mentioned is the poten-
tial for increased uncertainty when estimates of treatment
effects are based on small patient populations – for ex-
ample, “The trouble is that once you get into personalized
medicine, each time you look at a smaller subgroup of an
extra factor in terms of the evidence of benefit then you get
more uncertainty” (clinician). Furthermore, the implemen-
tation of stratification using CDs could contribute to un-
certainty (academic, clinician), and increasing medicine
complexity could lead to errors (clinician). It was noted
that use of real-world evidence to supplement gaps in ran-
domized clinical trials could generate significantly more
data and find better biomarkers that can help guide treat-
ment. A number of experts also noted a need for the col-
lection of more information on biomarkers and disease
(two payers), more genomic sequencing (clinician), as well
as more and larger trials (payer, clinician).
Discussion
Current definitions of PM focus either on demographic
criteria or on the use of clinical and biological informa-
tion, including genetic disposition and biomarkers, to im-
prove stratification of patients to receive optimized
treatments. The results of the literature review and expert
interviews described here show that these approaches –
‘physiology-based PM’ – are receiving a significant level of
attention in the literature and in clinical practice. Al-
though the findings of our survey were analysed in a quali-
tative way, they matched those obtained by Schleidgen
and colleagues [3], who analysed the literature, categorized
and quantified the results until they concluded that PM
“seeks to improve stratification and timing of health care”
by using biological information and biomarkers [3]. The
use of biomarkers in treatment decisions is important,
and there is a clear need to improve the systems for mak-
ing relevant tests for biomarkers or specific genetic char-
acteristics available alongside new medicines. In particular,
the assessment of the value of a medical treatment and its
associated CD together rather than separately is likely to
simplify the assessment of both.
It is worth noting that part of our findings suggest that
PM could be a holistic methodology, which is “centered
around the needs of individual patient” as stated before
[3]. Indeed, although the holistic vision of PM is con-
fined to a reduced number of published articles [13, 38],
it is plausible that offering more therapeutic options, as
it occurred in some diseases over the last few years,
means giving a growing weight to patients’ needs during
the decision-making process.
What has been recorded during interviews largely
matches the findings of literature survey, as briefly pre-
sented in the paragraph above. However, some import-
ant themes have been identified in the interviews. First,
the majority of experts did agree with the physiological
definition of PM, which should be based on a test (what-
ever the assay could be) to improve patients’ stratifica-
tion and treatment, both in terms of efficacy and
tolerability. This definition matches that synthesized by
Schleidgen et al., (2013) [3], which excludes the possibil-
ity that patients’ preferences could have an influence on
therapeutic management. This is not surprising, and it
could depend on several different factors, such as the
need to reduce uncertainty and to objectively stratify
Table 3 Interview respondents’ views on motivation for patient segmentation
Benefits Experts
Avoiding side effects/optimize side effect profile Academics (3), clinical experts (2), economic experts (3), EFPIA representative (1), patient
representatives (2)
Avoiding waste of resources/over-treating/selecting only
patients who need it
Academic (1), clinical experts (2), economic experts (3), EFPIA representative (1), patient
representatives (2), payer (1)
Improved outcomes in terms of effectiveness/efficacy Academic (1), clinical expert (1), economic experts (3), patient representative (1), payer
(1)
Better outcome/benefit/response rate (not specified) Academic (1), clinical experts (2), economic experts (2), provider (1)
Improved cost-effectiveness/value for money Clinical expert (1), economic experts (3), payer (1)
Reduce costs Economic experts (3), payer (1)
Improved length of life Academic (1), clinical expert (1), economic expert (1)
Improved quality of life Academic (1), economic expert (1)
Free-up time from clinicians Patient representative (1), payer (1)
EFPIA, the European Federation of Pharmaceutical Industries and Associations
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patients according to their individual probability or risk of
experiencing a therapeutic benefit or toxic effects, respect-
ively. Interestingly, further points of discussion about PM
were identified by the interviewees. Indeed, some experts
referred to the application of PM protocols as possible
causes of uncertainty, while a patients’ representative
stated that PM could impede some patients to get access
to potentially beneficial treatments. Those issues are very
similar and they are not completely new for medicine, be-
cause the adoption of some screening procedures could
result in erroneous values, thus denying therapeutic op-
portunities to some patients. It is likely that the develop-
ment of a CD in parallel with the drug may improve the
technical characteristics of the test.
The panorama is completed by the impact of PM for
patients, the third aspect. Indeed, disclosing and discuss-
ing results of tests with the patients will turn into an in-
formed decision making, as one patients’ representative
stated. It is interesting to note that although not explicit,
every shared decision making is based on the doctor-
patient relationship and does include patient’s prefer-
ences [48]. In a wider view, the discussion concerning a
pharmacological option for a disease does mean taking
patient’s preferences into account. Indeed, Schleidgen
and colleagues discussed about the possibility that PM
“is not a new concept as medicine has always been indi-
vidualized” [3]. Unfortunately, that assumption does not
match with the influence of individual needs and beliefs
on treatments that was neglected by the majority of
experts.
Overall, the present study suggests that there was little
mention in the literature or in the interview results of
the use of patients’ behaviour, beliefs, values, personal
environment and individual preferences in treatment de-
cisions and the related trade-offs. In particular, there was
little evidence for formal incorporation of patient prefer-
ences, utilities and social/cultural characteristics into the
evaluation of new medicines. Few of the interviewees
mentioned HRQoL, suggesting that most stratification is
based on individual, but not personal, factors.
We believe that to become truly personalized, medi-
cine will need decision making processes that can help
define therapeutic solutions adapted to an individual pa-
tient’s profile, including not only their clinical character-
istics or genetic disposition, but also their environment
and individual preferences.
In addition to disease characteristics and the results of
diagnostic tests, it will be important to take into account
other patient’s characteristics. Medication adherence and
disease management can be affected by patients’ personal
environment, and by behavioural factors, such as their
knowledge, abilities, occupation, social status, cultural
background and beliefs [49]. Patients may also have indi-
vidual preferences for particular treatment modalities, the
avoidance of certain side effects [50], and the benefit–
harm trade-off of interventions, and may differ in the level
of priority they give to health compared with other
problems.
PM will therefore need to actively involve patients in the
choice of the optimal therapeutic solution for them – to
achieve this patients will need information about the dis-
ease, the effectiveness of each therapy and the correspond-
ing side effect profiles in order to make an informed
decision. In this way, the goal of healthcare providers and
patients will be to minimize side effects, secure outcomes
and benefits, improve efficacy and HRQoL, and optimize
the benefit–harm balance for each individual. By matching
the characteristics of the selected therapy to a patient’s
lifestyle and preferences, common reasons for non-
adherence to prescribed treatments may be avoided, po-
tentially increasing the expected therapeutic benefits, as
well as optimizing the use of available healthcare re-
sources. In principle, PM should therefore benefit both
the individual patient and society. From a healthcare sys-
tem perspective, the benefits of PM are likely to be im-
proved outcomes and increased cost-effectiveness through
selection of the best treatment for each patient.
Personalization of medicine may therefore take a number
of forms not including only a laboratory test (i.e., a bio-
marker) but also individual preferences. For example,
androgen-deprivation therapy is an option for the treatment
of localized prostate cancer, but can cause impairment of
urogenital function [51] as well as radical prostatectomy
[52, 53]. The benefit–harm ratio for aggressive treatments
may therefore be very different between individual patients,
depending on their lifestyles and individual preferences –
this could lead to very different estimates of patient-
relevant outcomes and cost-effectiveness, depending on
what patient population is being considered [54]. In a wider
view, the application of PM may also encompass, for ex-
ample, not only patients’ preferences but also social con-
straints [55], risk perception of a disease and, in an
informed way, decision making [56].
A major challenge in the implementation of PM
based on patients’ preferences as well as their physi-
ology will be how best to capture preferences in the
assessment of new pharmaceutical products and diag-
nostics. Patients’ lifestyle, occupation and personal
preferences may significantly change the value of a
particular intervention from individual to individual
and for the same individual on the basis of different
situations/conditions, thus requiring a systematic clas-
sification (taxonomy) of outcomes or quality of life
according to patients’ needs. These differences are
likely to add to the complexity of HTA processes,
particularly in systems that rely on willingness-to-pay
thresholds in terms of cost per quality-adjusted life-
year to guide decision making. Once drugs are
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available for use based on both the results of diagnos-
tic tests and patients’ wishes, there will be a need for
appropriate information on treatment effectiveness
and side effect profiles that can be provided to
patients, and for validated tools that healthcare pro-
viders can use to collect individual patients’ prefer-
ences and their explicit trade-offs in an unbiased
manner. However, that approach will likely depend on
the availability of large databases on which tools
could be elaborated and validated. Demonstrating the
benefits of personalization of medicine beyond the
use of biomarkers will necessitate substantial evidence
generation after a product’s launch, through both
pragmatic trials and observational real-world studies.
Finally, effective personalization of medicine based on
patients’ environment and preferences will require an
understanding of how health outcomes are affected
by patients’ behaviour at individual and collective
levels. Therefore, it is likely that the implementation
of such an approach in the HTA processes will re-
quire several substantial changes.
The present study has several limitations. The lit-
erature search was not exhaustive, because the search
terms were not designed to identify publications in
areas such as behavioural science. Behavioural con-
cepts such as patient activation may have an import-
ant role to play in the development of PM [57]. In
addition, while attempts were made to interview
experts with a range of backgrounds, the number of
interviewees was limited. In particular, only two ex-
perts from Hungary, Italy and Spain, and one from
Sweden, were interviewed. Interview responses may
therefore not be fully representative of decision
makers in all countries. Similarly, the number of
patient group representatives was small, and their re-
sponses may not sufficiently reflect patients’ perspec-
tives. Finally, all interviewees did not answer some of
the questions, although all experts did respond to
items in each section of the interview guide.
Conclusions
In conclusion, the results of a literature review and a
series of expert interviews have shown that PM is fo-
cused on patient stratification according to individual
biological and clinical information. Although these ap-
proaches are important, incorporation of environmen-
tal factors and patients’ preferences in decision
making is also needed. We believe that, rather than
reducing patients to their disease, they must be
viewed holistically as human beings with individual
values within an overall social context. In future, PM
should move from treating diseases to managing pa-
tients, taking into account all individual factors.
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